Company intelligence / Profile preview

InnoPharmax Inc.

Taipei, Taipei City, Taiwaninnopharmax.com ↗

Ownership: Public · 4172
Employees: ~33
Development stage: Other

Overview

InnoPharmax has multiple approved products including Innomustine® (Bendamustine) which received NDA approval from Taiwan FDA in 2011 and was approved for National Health Insurance coverage in 2024. The company also has D07001 (Gemcitabine Oral Formulation) which received US FDA IND approval and is heading to global phase 3 pivotal study as an orphan drug.

Therapeutic areas: OncologyImmunologyRare DiseasesInfectious Diseases
Modalities: Small moleculesOral formulations
Industry: Biotech

Drug pipeline

1 asset

D07001-F4

Partnerships

SymBio PharmaceuticalsChina New Age Pharmaceutical Co., Ltd.HEC (1558.HK)BL&H Co. Ltd.Shenzhen Rosso Pharmaceutical Co. LtdAkornAvir PharmaShandong New Times Pharmaceuticals

Financials

Market cap: $32.5M
Total revenue: $2.1M
Enterprise value: $24.8M

Beyond the preview

Go deeper on InnoPharmax Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InnoPharmax Inc..